PQQ (Pyrroloquinoline Quinone)

Evidence Level
Limited
2 Clinical Trials
4 Documented Benefits
2/5 Evidence Score

Pyrroloquinoline quinone (PQQ) is a redox-active coenzyme that behaves as an antioxidant in laboratory tests, naturally present in human breast milk, soil bacteria, and trace amounts in foods. In cell and animal work it stimulates mitochondrial biogenesis — the growth of new mitochondria — and it has been studied in people mainly for cognitive function. No human study has tested whether it affects aging or lifespan. It is often combined with CoQ10, though the pairing has only been tested in a Japanese manufacturer report that is not indexed in PubMed, so treat the synergy claim as marketing.

Studied Dose 10–20 mg/day; 20 mg most studied for cognitive effects; often combined with 200–300 mg CoQ10
Active Compound Pyrroloquinoline quinone disodium salt (PQQ) — BioPQQ® (Mitsubishi Gas Chemical) and mnemoPQQ (Ryusendo) are the branded forms used in the published human trials

Benefits

Mitochondrial biogenesis (laboratory evidence)

PQQ activates PGC-1α and Nrf2 transcription factors that drive the production of new mitochondria — a process called mitochondrial biogenesis. That signalling work comes from cells and animals. No human trial cited here measured endurance, exercise capacity or metabolic efficiency.

Cognitive function and memory

Two 12-week randomised placebo-controlled trials of PQQ disodium salt, at 20 to 21.5 mg a day, reported gains in memory and attention. One showed clear improvements against placebo in adults averaging about 70; the other reported memory gains at 12 weeks in adults aged 20 to 65 without stating a placebo comparison in its abstract. Both were run by or with people tied to PQQ manufacturers, and neither measured fatigue. Improvements in cerebral blood flow and neuronal energy metabolism are proposed mechanisms.

Antioxidant activity in laboratory tests

In test tube chemistry PQQ can be reduced and re-oxidised many times over without being used up — a property that marketing turns into a claim that PQQ beats vitamin C. Two antioxidants that work in different parts of the cell cannot be ranked by counting cycles, and no head to head comparison has been run in people.

Nerve growth factor signaling (laboratory work)

In cultured cells, PQQ increases NGF (nerve growth factor) synthesis and secretion, supporting neuronal survival, neurite outgrowth, and synaptic plasticity. This has been seen in cell and animal work only. It has not been shown in people taking PQQ, and it is not a treatment for any nerve or brain condition.

Mechanism of action

1

PGC-1α activation and mitochondrial biogenesis

PQQ activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) — the master regulator of mitochondrial biogenesis. PGC-1α upregulation triggers expression of genes involved in building new mitochondria. This pathway has been mapped in cells and rodents; it has not been measured in human tissue after supplementation.

2

Catalytic redox cycling

Unlike classical antioxidants that are consumed in neutralizing free radicals, PQQ undergoes repeated oxidation-reduction cycles in laboratory assays — continuously regenerating its antioxidant capacity. This catalytic mechanism is enabled by PQQ's quinone chemical structure.

3

CREB signaling and NGF synthesis

PQQ activates cAMP response element-binding protein (CREB), which drives NGF gene transcription in neuronal cells. NGF supports the survival and function of cholinergic neurons critical for memory, learning, and cognitive function.

Clinical trials

1
PQQ for Cognitive Function in Healthy Older Adults — Clinical Trial

Randomized, double-blind, placebo-controlled trial of PQQ disodium salt (BioPQQ, 20 mg/day) for 12 weeks in 41 healthy elderly volunteers. (Adv Exp Med Biol — Itoh Y et al. 2016, 876:319-325, PMID 26782228)

41 healthy elderly volunteers.

The trial measured selective attention with the Stroop test and visual-spatial function with a tablet task. The change in Stroop interference was significantly smaller with PQQ than with placebo, which the authors read as better selective attention. On the tablet task the improvement appeared only in a subgroup with low baseline scores, not in the group as a whole. Composite memory was not measured in this trial. Critical caveat: small trial; industry-funded (Mitsubishi Gas Chemical, the major PQQ manufacturer). Effect sizes modest; independent peer-reviewed validation limited.

2
PQQ ± CoQ10 for Cognitive Performance — Clinical Trial

No indexed publication is cited for this card. The PQQ plus CoQ10 comparison comes from a Japanese manufacturer report (Koikeda T, Nakano M, Masuda K, Medical Consultation and New Remedies 2011;48:519-527) that is not indexed in PubMed and cannot be checked here; the summaries that do circulate describe 24 weeks of supplementation, not 12, and they disagree with each other on the number of participants and on the CoQ10 dose.

Healthy older adults.

The circulating summaries report better word memory with PQQ and with PQQ plus CoQ10, and better attention scores only in the combination group. None of that can be checked against a paper we can link, so treat it as a manufacturer claim rather than as evidence, and remember that a result from a combination says nothing about PQQ on its own.

Side effects and drug interactions

Common Potential side effects

Well tolerated at 10–20 mg/day in the trials published so far, which are small, mostly 12 weeks long and mostly run by manufacturers
No significant adverse effects reported at clinical doses
Headache is reported occasionally. European food regulators assessed PQQ disodium salt at up to 20 mg a day for healthy adults only; children and pregnant or breastfeeding women were left out of that assessment. The limiting finding in animal safety studies was on the kidneys, at doses far above supplement levels

Important Drug interactions

No established drug interactions at standard supplement doses (10–20 mg/day)
No human interaction studies have been published, so effects on medicines are unknown
Consult physician if taking immunosuppressants or chemotherapy

Frequently asked questions about PQQ (Pyrroloquinoline Quinone)

How much PQQ should I take?

Common doses are 10 to 20 mg per day. It is often combined with CoQ10, since the two are thought to complement each other in supporting mitochondria, the cell's energy producers.

What is PQQ used for?

PQQ (pyrroloquinoline quinone) is an antioxidant studied mainly for cognitive function. Its effects on mitochondria come from cell and animal work, and the heart claims are not backed by the studies cited on this page. It is popular in energy and longevity stacks, though the controlled human trials measured cognition rather than ageing or energy.

Should I take PQQ with CoQ10?

Many people do, because PQQ is thought to support the creation of new mitochondria while CoQ10 supports their energy output, so the pair is often marketed together for cellular energy. They can also be taken separately.

Is PQQ safe?

At typical doses of 10 to 20 mg, PQQ is generally well tolerated in studies. Long-term human safety data is still limited, so staying near studied doses is sensible. European food regulators assessed PQQ only for healthy adults, not for children or for pregnant or breastfeeding women, so it is best avoided in those groups. Check with your doctor if you take medicines.

What is PQQ?

Pyrroloquinoline quinone (PQQ) is a redox-active coenzyme that behaves as an antioxidant in laboratory tests, naturally present in human breast milk, soil bacteria, and trace amounts in foods.

What is the recommended dosage of PQQ?

The clinically studied dose is 10–20 mg/day; 20 mg most studied for cognitive effects; often combined with 200–300 mg CoQ10 Always follow the product label and check with a healthcare provider for personal advice.

Is PQQ safe, and does it have side effects?

For most healthy adults, PQQ is well tolerated at studied doses. Reported effects can include: Well tolerated at 10–20 mg/day in the trials published so far, which are small, mostly 12 weeks long and mostly run by manufacturers No significant adverse effects reported at clinical doses It may also interact with some medications. PQQ is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does PQQ interact with any medications?

Possible interactions include: No established drug interactions at standard supplement doses (10–20 mg/day) No human interaction studies have been published, so effects on medicines are unknown If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for PQQ?

NutraSmarts rates the evidence for PQQ as Limited (2 out of 5). It is backed by 2 clinical trials and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Baltic S, Nedeljkovic D, Todorovic N, Ranisavljev M, Korovljev D, et al. The impact of six-week dihydrogen-pyrroloquinoline quinone supplementation on mitochondrial biomarkers, brain metabolism, and cognition in elderly individuals with mild cognitive impairment: a randomized controlled trial. J Nutr Health Aging. 2024;28(8):100287..PubMedUsed to support: Six-week randomised trial of a dihydrogen-PQQ combination product (Alpha Hope), not PQQ alone, in 34 elderly people diagnosed with mild cognitive impairment. The primary endpoint, serum BDNF, did not differ significantly between groups (interaction P = 0.14). One ADAS-Cog subdomain, orientation, favoured the mixture (P = 0.03).
  2. Shiojima Y, Takahashi M, Takahashi R, Moriyama H, Bagchi D, Bagchi M, Akanuma M Effect of Dietary Pyrroloquinoline Quinone Disodium Salt on Cognitive Function in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study J Am Nutr Assoc. 2022;41(8):796-809. doi:10.1080/07315724.2021.1962770.PubMedUsed to support: Randomized, double-blind, placebo-controlled, parallel-group trial of PQQ disodium salt powder (mnemoPQQ, 21.5 mg/day) for 12 weeks. 64 healthy Japanese adults were randomized and 58 completed, with completer mean ages of about 71 and 72 despite an advertised range of 40 to under 80. Cognitrax composite memory, verbal memory, reaction time, complex attention, cognitive flexibility, executive function and motor speed improved versus placebo, as did the DECO forgetfulness questionnaire and MMSE-J, and no adverse events were reported. Four authors work for Ryusendo, the company that makes mnemoPQQ, and the paper carries a published correction.
  3. Tamakoshi M, Suzuki T, Nishihara E, Nakamura S, Ikemoto K Pyrroloquinoline quinone disodium salt improves brain function in both younger and older adults Food Funct. 2023;14(5):2496-2501. doi:10.1039/d2fo01515c.PubMedUsed to support: Double-blind, placebo-controlled trial of PQQ disodium salt 20 mg/day for 12 weeks in adults aged 20 to 65, reporting improved composite memory and verbal memory at 12 weeks. In the age-stratified analysis, only younger adults (20 to 40) improved on cognitive flexibility, processing speed and execution speed at 8 weeks, and only older adults (41 to 65) improved on complex and verbal memory at 12 weeks. The abstract gives no sample size, and three of the five authors work for Mitsubishi Gas Chemical, which manufactures PQQ.